ERBB2 and neoplasm: Positive rates of HER2 amplification, and overexpression in GC patients, are distinct and range from 10% to 27%, and 8.2% to 53.4%, respectively; this is likely due to differences in methodologies, ethnic groups, pathological types, and tumor locations among the affected patients (Vakiani, 2015).